8-Isoprostane as a marker of oxidative stress in nonsymptomatic cigarette smokers and COPD

European Respiratory Journal

Volumn 29, Issue 1, 2007, Pages 51-55

  Kinnula, Vuokko L ^a   Ilumets, H ^a   Myllarniemi M ^a   Sovijarvi A ^a   Rytila P ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Chronic obstructive pulmonary disease; Cigarette smoking; Oxidant; Sputum

Indexed keywords

8 ISOPROSTANE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MALE; NEUTROPHIL; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DINOPROST; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY VENTILATION; SMOKING; SPUTUM;

EID: 33846238535     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00023606     Document Type: Article

References (30)

1. Rahman I, MacNee W. Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radic Biol Med 1996; 21: 669-681.
2. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997; 156: 341-357.
3. Langen RC, Korn SH, Wouters EF. ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med 2003; 35: 226-235.
4. Boots AW, Haenen GR, Bast A. Oxidant metabolism in chronic obstructive pulmonary disease. Eur Respir J 2003; 46: Suppl. 22, 14s-27s.
5. Kharitonov SA, Robbins RA, Yates D, Keatings V, Barnes PJ. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med 1995; 152: 609-612.
6. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1693-1722.
7. Delanty N, Reilly M, Pratico D, FitzGerald DJ, Lawson JA, FitzGerald GA. 8-Epi PGF2 alpha: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. Br J Clin Pharmacol 1996; 42: 15-19.
8. Montuschi P, Barnes PJ, Roberts LJ. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004; 18: 1791-1800.
9. Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996; 94: 19-25.
10. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000; 162: 1175-1177.
11. Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003; 58: 294-298.
12. Kostikas K, Papatheodorou G, Psathakis K, Panagou P, Loukides S. Oxidative stress in expired breath condensate of patients with COPD. Chest 2003; 124: 1373-1380.
13. Carpagnano GE, Resta O, Foschino-Barbaro MP, et al. Exhaled interleukin-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Eur J Pharmacol 2004; 505: 169-175.
14. Rahman I. Reproducibility of oxidative stress biomarkers in breath condensate: are they reliable? Eur Respir J 2004; 23: 183-184.
15. Corradi M, Pignatti P, Manini P, et al. Comparison between exhaled and sputum oxidative stress biomarkers in chronic airway inflammation. Eur Respir J 2004; 24: 1011-1017.
16. Horvath I, Hunt J, Barnes PJ. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005; 26: 523-548.
17. Effros RM, Dunning MB III, Biller J, Shaker R. The promise and perils of exhaled breath condensates. Am J Physiol Lung Cell Mol Physiol 2004; 287: L1073-L1080.
18. Van Hoydonck PG, Wuyts WA, Vanaudenaerde BM, Schouten EG, Dupont LJ, Temme EH. Quantitative analysis of 8-isoprostane and hydrogen peroxide in exhaled breath condensate. Eur Respir J 2004; 23: 189-192.
19. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
20. Viljanen AA. Reference values for spirometric, pulmonary diffusing capacity and body plethysmographic studies. Scan J Clin Invest 1982; 42: Suppl. 159, 1-50.
21. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur Respir J 2002; 20: Suppl. 37, 1s-2s.
22. Rytila P, Rehn T, Ilumets H, et al. Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir Res 2006; 7: 69.
23. Montuschi P, Corradi M, Ciabattoni G, Nightingale J, Kharitonov SA, Barnes PJ. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med 1999; 160: 216-220.
24. Montuschi P, Ciabattoni G, Paredi P, et al. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 1998; 158: 1524-1527.
25. Wood LG, Fitzgerald DA, Gibson PG, Cooper DM, Garg ML. Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. Lipids 2000; 35: 967-974.
26. Wood LG, Garg ML, Simpson JL, et al. Induced sputum 8-isoprostane concentrations in inflammatory airway diseases. Am J Respir Crit Care Med 2005; 171: 426-430.
27. Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002; 166: 329-332.
28. Willemse BW, ten Hacken NH, Rutgers B, Postma DS, Timens W. Association of current smoking with airway inflammation in chronic obstructive pulmonary disease and asymptomatic smokers. Respir Res 2005; 6: 38.
29. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, Nilsson PM, Lofdahl CG. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005; 6: 98.
30. Stanescu D, Sanna A, Veriter C, Robert A. Identification of smokers susceptible to development of chronic airflow limitation: a 13-year follow-up. Chest 1998; 114: 416-425.